Tag: IR

SINGAPORE, July 28, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (NASDAQ: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today announced its financial results for the fiscal year ended March 31, 2025.

卡尔霍恩，佐治亚州, July 26, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) 今日宣布，公司 2025 年第二季度净收益为 1.47 亿美元，每股收益 (EPS) 为 2.34 美元；调整后净收益为 1.73 亿美元，调整后每股收益为 2.77 美元。 2025 年第二季度净销售额为 28 亿美元，按报告口径同比基本持平，按恒定工作日与汇率调整后同比下降 0.8%。 2024 年第二季度，公司报告净销售额 28 亿美元、净收益 1.57 亿美元、每股收益 2.46 美元；调整后净收益为 1.92 亿美元，调整后每股收益为 3.00 美元。

卡爾霍恩，喬治亞州, July 26, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc.（NYSE: MHK）今天宣布 2025 年第二季度淨盈利為 1.47 億美元，每股盈利（「EPS」）為 2.34 美元；調整後淨盈利為 1.73 億美元，調整後每股盈利為 2.77 美元。 2025 年第二季度報告淨銷售額為 28 億美元，與去年相比基本持平，按固定天數和匯率調整後與去年相比下降了 0.8%。 在 2024 年第二季度，公司報告淨銷售額為 28 億美元，淨盈利為 1.57 億美元，每股盈利為 2.46 美元；調整後淨盈利為 1.92 億美元，而調整後每股盈利則為 3.00 美元。

SHANGHAI, China, July 26, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. (“Pony.ai” or the “Company”) (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that it has received a permit to provide fully driverless commercial Robotaxi services of Shanghai’s Pudong New Area, issued at the World Artificial Intelligence Conference (“WAIC”) 2025. This achievement demonstrates not only increasing regulatory trust and recognition in the Company’s technology and safety standards, but also represents another major milestone in advancing Robotaxi commercialization in a top-tier urban market in China.

CHIHUAHUA, México, July 25, 2025 (GLOBE NEWSWIRE) -- Grupo Bafar, S.A.B. de C.V. (BIVA: BAFARB), a leading and benchmark company in the national food sector, announced its results for the second quarter of 2025, highlighting sustained growth driven by innovation, digitalization, and expansion strategies across all its divisions.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Today, KPN announces the completion of its € 250m share buyback, which commenced on 25 February 2025 and was completed on 25 July 2025. In total, KPN has repurchased 62,465,117 ordinary shares at an average price of € 4.00 per share.

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.